

- 2 -

*In the Specification:*

*Amendment to the Title of the Invention*

At page 1, please replace the title which reads: [Bispecific Molecules Having Clinical Utilities] with the following new title: --Bispecific Molecules For Use in Inducing Antibody Dependent Effector Cell-Mediated Cytotoxicity--.

*Amendment to the Detailed Description*

At page 5, line 6, please insert the following sentence after the phrase "ATCC Accession No. HB9469" - The hybridoma producing mAb 22 is available from the American Type Culture Collection, ATCC Accession No. HB12147.

*Amendment to the Abstract of the Invention*

At page 16, please replace the title which reads: [Bispecific Molecules Having Clinical Utilities] with the following new title: --Bispecific Molecules For Use in Inducing Antibody Dependent Effector Cell-Mediated Cytotoxicity--.

At page 16, please delete the current abstract which reads:

[Bispecific molecules comprising a target cell specific ligand and an effector cell specific antibody or functional antibody fragment are disclosed.]

and add the following new abstract:

• Bispecific molecules comprising a non-immunoglobulin tumor cell specific ligand and an antibody which binds the Fc receptor of an effector cell at a site that is not inhibited by endogenous immunoglobulin are disclosed. The bispecific molecules can be used to induce a specific antibody dependent effector cell-mediated cytotoxicity against tumor cells, such as small cell lung carcinoma (SCLC) cells, either *in vivo* or *in vitro*.